dacarbazine has been researched along with Venous Thromboembolism in 3 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (66.67) | 24.3611 |
2020's | 1 (33.33) | 2.80 |
Authors | Studies |
---|---|
Åkesson, L; Enblad, G; Fohlin, H; Glimelius, B; Glimelius, I; Goldkuhl, C; Lagerlöf, I; Molin, D; Palma, M | 1 |
Achawal, S; Dixit, S; Hingorani, M; Scott, I | 1 |
Davis, ME; Stoiber, AM | 1 |
2 review(s) available for dacarbazine and Venous Thromboembolism
Article | Year |
---|---|
The sequential use of carmustine wafers (Gliadel®) and post-operative radiotherapy with concomitant temozolomide followed by adjuvant temozolomide: a clinical review.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Chemotherapy, Adjuvant; Dacarbazine; Decanoic Acids; Drug Implants; Glioblastoma; Hematologic Diseases; Humans; Middle Aged; Multicenter Studies as Topic; Polyesters; Postoperative Care; Postoperative Complications; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Temozolomide; Venous Thromboembolism; Young Adult | 2011 |
Glioblastoma multiforme: enhancing survival and quality of life.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Dacarbazine; Glioblastoma; Humans; Neoplasm Recurrence, Local; Prognosis; Quality of Life; Radiotherapy; Seizures; Temozolomide; United States; Venous Thromboembolism | 2011 |
1 other study(ies) available for dacarbazine and Venous Thromboembolism
Article | Year |
---|---|
Limited, But Not Eliminated, Excess Long-Term Morbidity in Stage I-IIA Hodgkin Lymphoma Treated With Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine and Limited-Field Radiotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asthma; Bleomycin; Dacarbazine; Doxorubicin; Hodgkin Disease; Humans; Morbidity; Neoplasm Recurrence, Local; Neoplasm Staging; Venous Thromboembolism; Vinblastine | 2022 |